Medicine and research reference
Mazdutide
Human weight-management research on a GLP-1 and glucagon agonist, with country-specific approval context.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
What it is
Mazdutide is a dual agonist at GLP-1 and glucagon receptors.
Sources: Ji and colleagues, New England Journal of Medicine; indexed by Europe PMC
What GLORY-1 studied
The 2025 GLORY-1 report studied 610 adults in China with obesity or overweight and a related condition. In a 48-week placebo-controlled trial, both mazdutide groups had greater average weight reduction than placebo. Innovent funded the study. This population, trial formulation and follow-up period define the scope of its findings.
Sources: Ji and colleagues, New England Journal of Medicine; indexed by Europe PMC
Safety and geographical scope
Gastrointestinal events were most frequent and usually mild or moderate. Some participants stopped treatment because of adverse events. These findings do not establish every long-term or rare risk.
Sources: Ji and colleagues, New England Journal of Medicine; indexed by Europe PMC
Innovent announced Chinese NMPA approval for chronic weight management in June 2025. That manufacturer announcement concerns China and does not establish Australian or U.S. approval, or equivalence of online products.
Sources: Innovent Biologics
Published sources
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji and colleagues, New England Journal of Medicine; indexed by Europe PMC. Published 25 May 2025 online; accessed 6 September 2026.
Supports: GLORY-1: dual-receptor identity, Chinese study population, weight outcomes and reported adverse events.
- Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management
Innovent Biologics. Published 27 June 2025; accessed 6 September 2026.
Supports: Manufacturer announcement of Chinese approval, attributed as such. Not an Australian or U.S. registration record.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.